ライフサイエンスコーパス: metronomic

1 clarify the principles and underpinnings of metronomics.

2 performed to compare a low-dose, continuous, metronomic administration scheme with a more classical m

3 Growth-modulating effects of metronomic and maximum tolerated dose (MTD) regimens on

4 Whereas both metronomic and maximum tolerated dose delivery of CTX di

5 in the dose-dense arm and 5.0 months in the metronomic arm).

6 s 80% for the dose-dense arm and 69% for the metronomic arm; median OS was 17.1 months (95% CI, 14.0

7 Metronomic AT101 therapy increased mouse survival, decre

8 ation at rest, during autonomic challenge by metronomic breathing, a Valsalva manoeuvre and active st

9 Metronomic chemotherapy alone and combined with AEE788 r

10 concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.

11 targeted to disrupt pericyte support, while metronomic chemotherapy and/or VEGFR inhibitors target c

12 ional form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which

13 Metronomic chemotherapy does not improve 6-month PFS, co

14 ge, 15 years; 40 male [76.9%]) and 56 to the metronomic chemotherapy group (median age, 13 years; 42

15 months in the placebo group vs 96.4% in the metronomic chemotherapy group (P = .24).

16 However, clinical development of metronomic chemotherapy has been hampered by a number of

17 Although multiple mechanisms of benefit from metronomic chemotherapy have been proposed, how these me

18 Combination 3TSR and metronomic chemotherapy induced the greatest tumor regre

19 We found that metronomic chemotherapy induces functional normalization

20 Although the antitumor activity produced by metronomic chemotherapy is attributed widely to antiangi

21 Although oral metronomic chemotherapy is often used in progressive ped

22 Metronomic chemotherapy is the frequent administration o

23 Metronomic chemotherapy is usually associated with bette

24 To compare the effect of metronomic chemotherapy on progression-free survival (PF

25 ly measured the response of tumors to either metronomic chemotherapy or radiation therapy, where the

26 ls and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition.

27 same overall dose administered as a low-dose metronomic chemotherapy regimen largely prevented therap

28 rowth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against earl

29 sed tumor growth with low side effects using metronomic chemotherapy with GA.

30 Metronomic chemotherapy, defined as frequent administrat

31 In metronomic chemotherapy, frequent drug administration at

32 protocol, involving sequential MTD and then metronomic chemotherapy, overlaid with multitargeted inh

33 ptions regarding the mechanisms of action of metronomic chemotherapy, resulting in a set of 6 minimal

34 Metronomic chemotherapy, the delivery of doses in a low,

35 vessels is a key determinant of benefit from metronomic chemotherapy.

36 0.18-0.81; P = .01) appeared to benefit from metronomic chemotherapy.

37 a deeper, systems-level appreciation of the metronomics concept.

38 r a maximum tolerated dose (MTD) regimen, a "metronomic" continuous low-dose regimen, or a "chemo-swi

39 The combination of immunotherapy and metronomic CTX therapy may be well suited to clinical ma

40 Further analysis showed that metronomic CTX treatment did not delete cells with low e

41 with malignant pleural mesothelioma received metronomic cyclophosphamide and dendritic cell-based imm

42 nd that reduction of regulatory T cells with metronomic cyclophosphamide increased the efficacy of im

43 The combination of bevacizumab and metronomic cyclophosphamide is active in recurrent OC.

44 ion, but then rapid regrowth, in contrast to metronomic cyclophosphamide plus imatinib, which produce

45 ation with other modalities such as low-dose metronomic cyclophosphamide.

46 efficacious benefits that can be achieved by metronomic delivery of BH3-mimetic drugs, in particular

47 Combining this immunotherapeutic regime with metronomic delivery of CTX resulted in antitumor activit

48 in the taxane-sensitive cell lines, whereas metronomic docetaxel plus AEE788 had an additive effect

49 In vivo, metronomic docetaxel resulted in significant reduction o

50 combination therapy may be most useful when "metronomic" doses of antineoplastic drugs are used, ther

51 As metronomic dosing has shown tumor control capability, ev

52 the endothelial compartment of a tumor when metronomic dosing is employed.

53 knowledge of the coupled dynamics underlying metronomic dosing is neither sufficiently well developed

54 Metronomic dosing of chemotherapy-defined as frequent ad

55 The cytotoxic effects of MTD and metronomic dosing were tested with 3-(4,5-dimethylthiazo

56 antiangiogenic therapy can be engendered by metronomic dosing.

57 witch" regimen consisting of MTD followed by metronomic dosing.

58 l objective; and (2) that regularly spaced, "metronomic" dosing is the best way to achieve it.

59 Despite this, metronomic gemcitabine significantly inhibited tumor ang

60 Furthermore, metronomic gemcitabine yielded a 40%-50% decrease in tum

61 ure to gemcitabine was 14 times lower in the metronomic groups compared with the standard group.

62 Stable disease was maintained in the metronomic groups for up to 2 months after treatment com

63 Low-dose metronomic (LDM) chemotherapy, which utilizes lower, les

64 ty in mCRC could be increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination o

65 xpression of Omomyc, we now demonstrate that metronomic Myc inhibition not only contains Ras-driven l

66 docetaxel in combination with either daily (metronomic) or weekly (bolus) doses of AT101.

67 ivity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent

68 In an SCID mouse xenograft model, low-dose metronomic paclitaxel treatment decreased lung dissemina

69 of metastases but overall suggest use of the metronomic protocol.

70 Both metronomic protocols (0.5 and 1 mg/kg/day for 28 days) w

71 ly, our results confirmed the superiority of metronomic protocols in chemoresistant tumors in vivoCan

72 One arm received a 4-drug oral metronomic regimen of daily celecoxib and thalidomide wi

73 Metronomic regimens inhibited mobilization of CEPs (P <

74 Effects of metronomic regimens on circulating endothelial precursor

75 n this study, we show that a 6-day repeating metronomic schedule of cyclophosphamide administration a

76 nal cytotoxic chemotherapy administered on a metronomic schedule.

77 etion occurred with slower kinetics with the metronomic schedule.

78 ugs delivered with maximum tolerated dose or metronomic scheduling.

79 gies as compared with low-dose, high-density metronomic strategies (LDM) for tumors with different gr

80 Our results suggest that metronomic taxane chemotherapy with dual EGFR and VEGFR

81 We examined the efficacy of metronomic taxanes alone and in combination with AEE788-

82 In vitro, metronomic taxanes caused endothelial cell toxicity at 1

83 Both dose-dense and metronomic temozolomide regimens were well tolerated wit

84 that other therapies such as dose-dense and metronomic temozolomide regimens, targeted molecular age

85 re randomly assigned to dose-dense and 43 to metronomic temozolomide.

86 ly greater than that of high dose density or metronomic therapies.

87 template was applied to the development of a metronomic therapy backbone for neuroblastoma.

88 We therefore investigated whether such metronomic therapy with the alkylating agent cyclophosph

89 Several novel treatment modalities such as metronomic therapy, angiogenesis inhibitors, vascular di

90 d suggests guidelines for the optimal use of metronomic therapy.

91 ive approaches, to call a workshop on "Tumor Metronomics: Timing and Dose Level Dynamics" to explore